Abstract: The present invention relates to a transdermal patch mode of administration of topical synergistic anti-inflammatory formulation. The formulation comprises a blend 1 to 6% by weight of Cymbopogon citratus oil (CC oil); 0.5 to 6% by weight of Zanthoxylum armatum oil (ZA oil); 0.5 to 6% in weight by Hedychium spicatum oil (HS oil). The invention also provides a method of management of the pain and/or inflammation by the formulations coated on the transdermal patch of the invention.

Abstract: The present invention discloses a composition and method for treating viral infections. The composition and method deliver inhibitors for preventing the entry of SARS-Cov-2 viral infections and the emerging variants are disclosed. The composition comprises a protease inhibitor comprising calcium salt of Tranexamic acid (Ca-TA). The protease inhibitor further comprises lithium salt of Tranexamic acid (Li-TA). The composition demonstrates efficacy in fibrin clot systems, where the Ca salt shows unexpected behavior of clot swelling, unlike TA. This inhibitor blocks the peptide or enzyme known as plasmin from interacting with fibrin (a protein) and subsequently breaking it down. TA is a safe and commonly used small molecule drug. The Ca-TA inhibitor interferes with the binding of the viral spike protein of SARS-CoV-2 to the human cell surface receptor angiotensin-converting enzyme-2 (ACE-2) to avoid infections caused by SARS-CoV-2 infections and emerging variants.

Abstract: The present invention relates to a topical synergistic anti-inflammatory formulation comprising a blend 1 to 6% by weight of Cymbopogon citratus oil (CC oil); 0.5 to 6% by weight of Zanthoxylum armatum oil (ZA oil); 0.5 to 6% in weight by Hedychium spicatum oil (HS oil). The invention also provides a method of management of the pain and/or inflammation by the formulations of the invention.

Abstract: The disclosed invention provides a system and method of artificially retarding fibrin-based blood clot degradation via the sustained release of a protease inhibitor, such as, for example, aprotinin or tranexamic acid (“TA”). The sustained release of the protease inhibitor is accomplished through incorporation within a biodegradable polymer microsphere to produce a protease inhibitor formulation. Next, the formulation along with fibrinogen and thrombin is applied to a wound site where an outer surface of the polymer microsphere degrades in a proteolytic environment to expose and release the incorporated protease inhibitor to the surrounding hydrogel or sealant or clot matrix at the wound site.

Abstract: The present invention relates to a topical synergistic anti-inflammatory formulation comprising a blend 1 to 6% by weight of Cymbopogon citratus oil (CC oil); 0.5 to 6% by weight of Zanthoxylum armatum oil (ZA oil); 0.5 to 6% in weight by Hedychium spicatum oil (HS oil). The invention also provides a method of management of the pain and/or inflammation by the formulations of the invention.

Abstract: The disclosed invention provides a system and method of artificially retarding fibrin-based blood clot degradation via the sustained release of a protease inhibitor, such as, for example, aprotinin or tranexamic acid (“TA”). The sustained release of the protease inhibitor is accomplished through incorporation within a biodegradable polymer microsphere to produce a protease inhibitor formulation. Next, the formulation along with fibrinogen and thrombin is applied to a wound site where an outer surface of the polymer microsphere degrades in a proteolytic environment to expose and release the incorporated protease inhibitor to the surrounding hydrogel or sealant or clot matrix at the wound site.

Abstract: The disclosed invention provides a system and method of artificially retarding fibrin-based blood clot degradation via the sustained release of a protease inhibitor, such as, for example, aprotinin or tranexamic acid (“TA”). The sustained release of the protease inhibitor is accomplished through incorporation within a biodegradable polymer microsphere to produce a protease inhibitor formulation. Next, the formulation along with fibrinogen and thrombin is applied to a wound site where an outer surface of the polymer microsphere degrades in a proteolytic environment to expose and release the incorporated protease inhibitor to the surrounding hydrogel or sealant or clot matrix at the wound site.